Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 101–200 of 1,004
Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Zimmermann, M., Patil, K. R., Typas, A., & Maier, L. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010116 · Cited by 121
“…gut microbiome impacts anticancer immunotherapy by PD-1 (Tanoue et al , 2019), CTLA-4 blockage (V (cid:2) etizou et al , 2015; Sivan et al , 2015; Mager et al , 2020) or in cyclophosphamide therapy (Viaud et al , 2013), all resulting in findings of high transferability to humans (reviewed in…”
Liu, Y., Lu, Y., Ning, B., Su, X., Yang, B., Dong, H., Yin, B., Pang, Z., & Shen, S. (2022) · ACS Nano · doi:10.1021/acsnano.1c09818 · Cited by 121
The gut microbiome and cancer: from tumorigenesis to therapy
Nobels, A., van Marcke, C., Jordan, B. F., Hul, M. V., & Cani, P. D. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01287-w · Cited by 136
“…produced by Bifidobacterium pseudolongum in the gut was able to reach A2A receptors of T lymphocytes infiltrating tumours and improved the efficacy of anticancer immunotherapy in mice 189,195 , further supporting the notion that the gut microbiota has a role in the prognosis of tumour development.”
Zhu, J., Ke, Y., Liu, Q., Yang, J. D., Liu, F., Xu, R., Zhou, H., Chen, A., Xiao, J., Meng, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35130-7 · Cited by 130
Gao, G., Shen, S., Zhang, T., Zhang, J., Huang, S. W., Sun, Z., & Zhang, H. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104533 · Cited by 124
“22 Administration of Lacticaseibacillus rhamnosus GG could improve the antitumor activity of anti-PD-1 by increasing the cross-priming of CD8 + T cells with DCs through the cGAS/STING dependent type-I interferon production.”
Chen, L., Zhao, R., Shen, J., Liu, N., Zheng, Z., Yu, M., Zhu, J., Zhang, L., Wang, Y., Fang, H., et al. (2023) · Advanced Materials · doi:10.1002/adma.202306281 · Cited by 117
Intracellular bacteria in cancer—prospects and debates
Schorr, L., Mathies, M., Elinav, E., & Puschhof, J. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00446-9 · Cited by 120
Sun, J., Chen, F., & Wu, G. (2023) · The ISME Journal · doi:10.1038/s41396-023-01483-0 · Cited by 126
Gao, G., Ma, T., Zhang, T., Jin, H., Li, Y., Kwok, L.-Y., Zhang, H., & Sun, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772532 · Cited by 111
“pseudolongum could enhance immunotherapy response through metabolite production (18).”
BackgroundThe Cancer Microbiome: Recent Highlights and Knowledge Gaps
Knippel, R. J., Drewes, J. L., & Sears, C. L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0324 · Cited by 110
“longum promote anti-tumorigenic mechanisms (58,59).”
Lo, B. C., Kryczek, I., Yu, J., Vatan, L., Caruso, R., Matsumoto, M., Sato, Y., Shaw, M. H., Inohara, N., Xie, Y., et al. (2024) · Science · doi:10.1126/science.adh8342 · Cited by 118
Zhang, T., Li, Y., Zhai, E., Zhao, R., Qian, Y., Huang, Z., Liu, Y., Zhao, Z., Xu, X., Liu, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2580 · Cited by 127
“However, gastric cancer represents a highly heterogeneous malignant tumor, wherein most tumor tissues demonstrate an immunosuppressive state, significantly affecting the effectiveness of immune checkpoint inhibitor therapy (60–62).”
Ševčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 112
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 135
Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
Szczyrek, M., Bitkowska, P., Chunowski, P., Czuchryta, P., Krawczyk, P. A., & Milanowski, J. (2021) · Nutrients · doi:10.3390/nu13072217 · Cited by 113
“The abundance of Akkermansia muciniphila correlated with a better response to immunotherapy in lung carcinoma [93], renal cell carcinoma [72,93], and urothelial carcinoma patients [72].”
BackgroundGut microbiota-derived metabolites in CRC progression and causation
Dalal, N., Jalandra, R., Bayal, N., Yadav, A. K., Harshulika, Sharma, M., Makharia, G. K., Kumar, P., Singh, R. K., Solanki, P. R., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03729-w · Cited by 113
Lu, Y., Li, Y., Liu, Q. F., Du, P., Du, P., Zhu, F., Han, Y., Liu, X., Liu, X., Wang, X., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.041 · Cited by 107
Aghamajidi, A., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14153563 · Cited by 110
Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100
“In addition, no treatment to restore the decreased therapeutic efficacy of ICB in patients receiving PPIs is available.4,5,13 In the current study, we showed PPI use was independently associated with shorter OS in NSCLC patients treated with ICB, which is consistent with the findings of previous studies.18,19 PPIs ten…”
BackgroundInfluentialEmerging targetome and signalome landscape of gut microbial metabolites
Zheng, X., Cai, X., & Hao, H. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.011 · Cited by 101
Pingili, A. K., Chaib, M., Sipe, L. M., Miller, E. J., Teng, B., Sharma, R., Yarbro, J. R., Asemota, S., Abdallah, Q. A., Mims, T. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109285 · Cited by 104
“Fecal microbial transplant of such ICB responder’s fauna reduced melanoma and other cancer progression in mice through the microbially derived metabolite inosine (Matson et al., 2018; Mager et al., 2020; Peng et al., 2020).”
BackgroundGut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Xie, J., Liu, M., Deng, X., Tang, Y., Zheng, S., Ou, X., Tang, H., Xie, X., Wu, M., & Zou, Y. (2024) · iMeta · doi:10.1002/imt2.156 · Cited by 108
“Inosine produced by a subset of intestinal bacteria increases antitumor immunity through enhancing Th1 differentiation and effector function of naïve T cells expressing A2AR [64].”
BackgroundGut Microbiome in Colorectal Cancer: Clinical Diagnosis and Treatment
Liu, Y., Lau, H. C.-H., Cheng, W. Y., & Yu, J. Q. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.07.002 · Cited by 119
“terium pseudolongum produces the metabolite inosine to enhance the anti-CTLA-4 immunotherapeutic response through activating A2AR expressed in antitumor T cells [84].”
BackgroundInfluentialMicrobiota-driven mechanisms at different stages of cancer development
Ivleva, E., & Grivennikov, S. I. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100829 · Cited by 103
Promising dawn in tumor microenvironment therapy: engineering oral bacteria
Wang, Z., Sun, W., Hua, R., Wang, Y., Li, Y., & Zhang, H. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00282-3 · Cited by 97
Inosine: A bioactive metabolite with multimodal actions in human diseases
Kim, I. S., & Jo, E.-K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1043970 · Cited by 101
“Inosine treatment also results in the activation of anti-tumor and anti-inflammatory responses in different disease models (Haskó et al., 2000; Mabley et al., 2003; Panebianco et al., 2018; Tobólska et al., 2018; Kovachev, 2020; Mager et al., 2020).”
BackgroundInfluentialMechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Yang, M., Cui, M., Sun, Y., Liu, S., & Jiang, W. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01711-w · Cited by 108
“Intestinal Bifidobacterium pseudolongum produces inosine, which stimulates T helper type 1(Th1) cells by binding to T cell A2ARs, boosting anti-PD-1 or anti-CTLA-4 effectiveness [68] (Fig.”
BackgroundGonzález-Loyola, A., Bovay, E., Kim, J., Lozano, T. W., Sabine, A., Renevey, F., Arroz-Madeira, S., Rapin, A., Wypych, T. P., Rota, G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf4335 · Cited by 94
Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalnikova, H. K., Cizkova, J., Cizkova, V., Palanova, A., Horak, V., & Mrazek, J. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02458-5 · Cited by 93
Yang, J. H., Wei, H., Lin, Y., Chu, E. S., Zhou, Y., Gou, H., Guo, S., Lau, H. C.-H., Cheung, A. H. K., Chen, H., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.10.012 · Cited by 104
Nutrients: Signal 4 in T cell immunity
Raynor, J. L., & Chi, H. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20221839 · Cited by 108
“…that promote T cell function under glucose and glutamine-restricted conditions, including inosine and acetate (Klysz et al., 2024; Leone et al., 2019; Mager et al., 2020; Qiu et al., 2019; Wang et al., 2020b), provides additional approaches to condition T cells for enhanced efficacy of ACT.”
BackgroundThe human microbiome and cancer: a diagnostic and therapeutic perspective
Kandalai, S., Li, H., Zhang, N., Peng, H., & Zheng, Q. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2240084 · Cited by 101
“pseudolongum was found to produce the metabolite inosine, which could improve anti-tumor immune functions.(134) Additionally, the fungal order Capnodiales and its genus Cladosporium, commonly found as members of the human mycobiome, were shown to be more prevalent in melanoma patients that did not respond to immune ch…”
BackgroundCrosstalk between gut microbiota and host immune system and its response to traumatic injury
Ullah, H., Arbab, S., Tian, Y., Chen, Y., Liu, C., Li, Q., & Li, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1413485 · Cited by 111
“Th1 differentiation and effector activity are enhanced in naïve T cells by the gut microbiota-derived metabolite inosine, which is generated by Bi fi dobacterium and A. muciniphila (37).”
BackgroundZhang, S.-L., Han, B., Mao, Y.-Q., Zhang, Z.-Y., Li, Z.-M., Kong, C.-Y., Wu, Y., Chen, G.-Q., & Wang, L.-S. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2046246 · Cited by 89
“johnsonii and Olsenella, and found that oral administration of these species could significantly enhance the therapeutic effect of immune checkpoint inhibitors in tumor models.(10)”
BackgroundGut microbiome-mediated metabolism effects on immunity in rural and urban African populations
Stražar, M., Temba, G. S., Vlamakis, H., Kullaya, V. I., Lyamuya, F., Mmbaga, B. T., Joosten, L. A. B., van der Ven, A. J. A. M., Netea, M. G., de Mast, Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25213-2 · Cited by 91
Li, M., Liu, N., Zhu, J., Wu, Y., Niu, L., Liu, Y., Chen, L., Bai, B., Miao, Y., Yang, Y., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122584 · Cited by 103
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 107
“Interestingly, inosine efficacy was dependent on CpG oligode-oxynucleotide co-stimulation, demonstrating the context-dependent nature of microbiome–immune system cross-talk 180 .”
InfluentialLin, A., Xiong, M., Jiang, A., Huang, L., Wong, H. Z. H., Feng, S., Zhang, C., Yu, H., Chen, L., Chi, H., et al. (2025) · iMeta · doi:10.1002/imt2.70070 · Cited by 108
Weiß, A. S., Niedermeier, L., von Strempel, A., Burrichter, A. G., Ring, D., Meng, C., Kleigrewe, K., Lincetto, C., Hübner, J., & Stecher, B. (2023) · Nature Communications · doi:10.1038/s41467-023-40372-0 · Cited by 116
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Self-citationKaźmierczak-Siedlecka, K., Roviello, G., Catalano, M., & Połom, K. (2021) · Nutrients · doi:10.3390/nu13082674 · Cited by 99
“revealed [63] that Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species were able to significantly improve the efficacy of ICIs in mouse models of cancer.”
BackgroundHuang, Y., Zhu, N., Zheng, X., Liu, Y., Lu, H., Yin, X., Hao, H., Tan, Y., Wang, D., Hu, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.785422 · Cited by 86
“Metabolic Pathways Associated With Microbial Communities From LTS and STS Patients Several studies have shown that microbiome can change tumor microenvironment through producing metabolites (13, 32).”
BackgroundEmerging mechanisms and promising approaches in pancreatic cancer metabolism
Wu, H., Fu, M., Wu, M., Cao, Z., Zhang, Q., & Liu, Z. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06930-0 · Cited by 102
“Several microorganisms that act on the adenosine pathway have been found to enhance the ef fi cacy of immune checkpoint blockade (ICB) [235].”
BackgroundThe gut microbiome in disorders of gut–brain interaction
Kraïmi, N., Ross, T., Pujo, J., & Palma, G. D. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2360233 · Cited by 100
“111 Altogether, these studies highlight how microbial influence on gut-brain communication may occur through multiple routes; thus, the discovery of specific pathways of action will lead to better tailored treatments for microbiome-gut-brain axis disorders.”
BackgroundRuan, Y., Yuan, P., Li, P.-Y., Chen, Y., Fu, Y., Gao, L., Wei, Y., Zheng, Y., Li, S.-F., Feng, W.-S., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116503 · Cited by 89
The emerging role of microbiota-derived short-chain fatty acids in immunometabolism
Jasim, S. A., Opulencia, M. J. C., Ramírez‐Coronel, A. A., Abdelbasset, W. K., Abed, M. H., Markov, A. A., Al‐Awsi, G. R. L., Shamsiev, J. A., Hammid, A. T., Shalaby, M. N., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108983 · Cited by 96
Tumor microbiome – an integral part of the tumor microenvironment
Čierniková, S., Ševčíková, A., Števurková, V., & Mego, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1063100 · Cited by 92
Tumor hijacks macrophages and microbiota through extracellular vesicles
Jiang, J., Mei, J., Ma, Y., Jiang, S., Zhang, J., Yi, S., Feng, C., Liu, Y., & Liu, Y. (2022) · Exploration · doi:10.1002/exp.20210144 · Cited by 91
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 92
Inhibition of UBA6 by inosine augments tumour immunogenicity and responses
(2022) · doi:10.1038/s41467-022-33116-z · Cited by 82
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 81
Schirmer, M., Stražar, M., Ávila-Pacheco, J., Rojas‐Tapias, D. F., Brown, E., Temple, E. R., Deik, A., Bullock, K. H., Jeanfavre, S., Pierce, K. A., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2023.12.013 · Cited by 94
Li, X., Shang, S., Wu, M., Song, Q., & Chen, D. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217096 · Cited by 92
Sarkar, O. S., Donninger, H., Rayyan, N. A., Chew, L. C., Stamp, B. F., Zhang, X., Whitt, A. G., Li, C., Hall, M. B., Mitchell, R. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3736 · Cited by 86
“9, eadg3736 (2023) 30 June 2023 11 of 16 is possible that CD73 expression could be up-regulated in these circulating monocytes upon their infiltration into the PGE2-enriched TME.”
BackgroundInfluentialDing, X. Q., Ting, N. L.-N., Wong, C. C., Huang, P., Бакурадзе, Н., Jiang, L., Liu, C., Lin, Y., Li, S., Liu, Y., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.05.004 · Cited by 90
Microbiota-driven antitumour immunity mediated by dendritic cell migration
Lin, Y.-T., Fukuoka, S., Koyama, S., Motooka, D., Tourlousse, D. M., Shigeno, Y., Matsumoto, Y., Yamano, H., Murotomi, K., Tamaki, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09249-8 · Cited by 90
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy
Lv, Y., Li, Z., Liu, S., Zhou, Z., Jinling, S., Ba, Y., Weng, S., Zuo, A., Xu, H. W., Luo, P., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02407-6 · Cited by 98
“Notably, tenalisib further exerts therapeutic efficacy by modulating PI3Kδ/γ-related metabolism to limit malignant T cell and cancer cell proliferation directly [245].”
Predicting drug-microbiome interactions with machine learning
McCoubrey, L. E., Gaisford, S., Orlu, M., & Basit, A. W. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107797 · Cited by 79
Gut microbiome in gastrointestinal cancer: a friend or foe?
Liu, Y., Baba, Y., Ishimoto, T., Gu, X. J., Zhang, J., Nomoto, D., Okadome, K., Baba, H., & Qiu, P. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69331 · Cited by 85
“The metabolite Inosine derived from Bifidobacterium pseudolongum promotes Th1 cell differentiation and enhances the therapeutic effect of ICIs, and this process is mediated by T-cell specific adenosine A2A receptor signaling in a mouse model of CRC [149].”
BackgroundMicrobial metabolites in colorectal tumorigenesis and cancer therapy
Liu, Y., Lau, H. C.-H., & Yu, J. Q. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2203968 · Cited by 89
The gut microbiome and cancer response to immune checkpoint inhibitors
Gazzaniga, F. S., & Kasper, D. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184321 · Cited by 92
“(13) ferences between the recipients.”
InfluentialWei, Z., Yang, B., Tang, T., Xiao, Z., Ye, F., Li, X., Wu, S., Huang, J., & Jiang, S. (2023) · Cancer Medicine · doi:10.1002/cam4.5772 · Cited by 96
Dietary interventions and precision nutrition in cancer therapy
Martínez-Garay, C., & Djouder, N. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.04.004 · Cited by 85
Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment
Yang, X., Guo, Y., Chen, C., Shao, B., Zhao, L., Zhou, Q., Liu, J., Wang, G., Yuan, W., & Sun, Z. (2021) · Immunology · doi:10.1111/imm.13397 · Cited by 86
“However, the effect of inosine on T cells requires sufficient costimulation to enable IL12 receptors to participate in Th1 differentiation and produce IFNγ to achieve effective antitumour immunity [50].”
BackgroundFecal microbiota transplantation: no longer cinderella in tumour immunotherapy
Yang, Y., An, Y., Dong, Y., Chu, Q., Wei, J., Wang, B., & Cao, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104967 · Cited by 90
Wu, L., Zhou, J., Zhou, A., Lei, Y., Tang, L., Hu, S., Wang, S., Xu, X., Chen, Q., Tu, D., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2390176 · Cited by 96
“23 For example, Lactobacillus significantly enhanced the efficacy of tumor resistance against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 33 and prevented idiopathic eczema in infancy.”
BackgroundZhu, X., Hu, M., Huang, X., Li, L., Lin, X., Shao, X., Li, J., Du, X., Zhang, X., Sun, R., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.12.013 · Cited by 94
Li, S., Yang, S., Zhou, Y., Disoma, C., Dong, Z., Du, A., Zhang, Y., Chen, Y., Huang, W., Chen, J., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.712081 · Cited by 87
“COVID-19 has emerged not only as a respiratory disease that mainly affects the lungs but also as a multiorgan disease that inflicts damage to other organ systems including the nervous and gastrointestinal (GI) systems (Mao et al., 2020; Patel et al., 2020; Tian J. et al., 2020; Wong et al., 2020).”
BackgroundDing, G., Gong, Q., Ma, J., Liu, X., Wang, Y., & Cheng, X. (2021) · Cancer Science · doi:10.1111/cas.15078 · Cited by 81
Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response
Yan, F., Zhang, Q., Shi, K., Zhang, Y., Zhu, B., Bi, Y., & Wang, X. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1152987 · Cited by 91
The heightened importance of the microbiome in cancer immunotherapy
Villemin, C., Six, A., Neville, B. A., Lawley, T. D., Robinson, M. J., & Bakdash, G. (2023) · Trends in Immunology · doi:10.1016/j.it.2022.11.002 · Cited by 73
The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Tekle, G. E., Andreeva, N., & Garrett, W. S. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-025619 · Cited by 86
A dynamic atlas of immunocyte migration from the gut
Galván-Peña, S., Zhu, Y., Hanna, B. S., Mathis, D., & Benoist, C. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi0672 · Cited by 74
The Microbiome and Cancer: A Translational Science Review
Fernandez, E., Wargo, J. A., & Helmink, B. A. (2025) · JAMA · doi:10.1001/jama.2025.2191 · Cited by 95
Lu, L., Dong, J., Liu, Y., Qian, Y., Zhang, G., Zhou, W., Zhao, A., Ji, G., & Xu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964793 · Cited by 76
“Metabolites of the gut microbiota have also become biomarkers to predict beneficial outcomes of ICI treatment (Mager et al., 2020).”
BackgroundVisual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021
Ma, L., Ma, J., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843106 · Cited by 72
Qiu, J., Chen, L., Zhang, L., Xu, F., Zhang, C., Ren, G. R., Chang, K., He, G., Du, Z., Le, Y., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155111 · Cited by 74
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 89
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 83
Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies
Zhou, M., Tang, Y., Xu, W., Hao, X., Li, Y., Huang, S. Q., Xiang, D., & Wu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140463 · Cited by 92
“pseudolongum-derived inosine could enhance antitumor immunity by co-stimulation (68).”
BackgroundKonen, J. M., Wu, H., & Gibbons, D. L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.006 · Cited by 82
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response
Zhang, H., Fu, L., Leiliang, X., Qu, C., Wu, W., Wen, R., Huang, N., He, Q., Cheng, Q., Liu, G., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12597 · Cited by 78
“Inosine released by Bifidobacterium pseudolongum can promote the activation of T cells in tumor tissue [189].”
BackgroundCao, M., Deng, Y., Hao, Q., Yan, H., Wang, Q., Dong, C., Wu, J., He, Y., Huang, L., Xia, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02226-7 · Cited by 84
“11,15,17,19,29 As validation, CT26 cells also exhibited sensitivity to PD-1 inhibitor treatment when initiated with a smaller tumor volume, 30 while the ef fi cacy was signi fi cantly diminished upon depletion of the gut microbiota (Supplementary Fig.”
Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases
Kutryb-Zając, B. A., Mierzejewska, P., Slominska, E. M., & Smolenski, R. T. (2020) · Molecules · doi:10.3390/molecules25204652 · Cited by 70
“From one side, inosine at micromolar concentrations expressed immunomodulatory and anti-inflammatory effects via A1R, A2AR and A3R [30,31].”
BackgroundInfluentialSampsell, K., Hao, D., & Reimer, R. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239239 · Cited by 81
“muciniphila in the upper gastrointestinal tract [6].”
BackgroundInfluentialThe elegant complexity of mammalian ecto-5′-nucleotidase (CD73)
Alcedo, K. P., Bowser, J. L., & Snider, N. T. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.05.008 · Cited by 77
Yang, Y., Liu, H., Chen, Y., Xiao, N., Zheng, Z., Liu, H., & Wan, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05757-5 · Cited by 78
“Recent preclinical and clinical studies have linked gut microbiota composition to specific and toxic responses to ICIs [168, 169].”
BackgroundJoachim, L., Göttert, S., Sax, A., Steiger, K., Neuhaus, K., Heinrich, P., Fan, K., Orberg, E. T., Kleigrewe, K., Ruland, J., et al. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104834 · Cited by 67
“19,30 A current subject of debate is to which degree bacterial-derived metabolites are able to alter antitumour effects of ICI therapy.”
BackgroundInfluentialBifidobacterium modulation of tumor immunotherapy and its mechanism
Pei, B., Peng, S., Huang, C., & Zhou, F. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03665-x · Cited by 73
“Several studies have shown that Bifidobacterium modulates the immune function and inhibits tumor cell proliferation by possibly regulating different pathway mechanisms, among others [56, 77–79].”
BackgroundInfluentialModulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
Wu, J., Wang, S., Zheng, B. J., Qiu, X., Wang, H., & Chen, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669150 · Cited by 83
“They also found that the antitumor effect of Akkermansia muciniphia in human also relies on inosine-A2AR signal (Figure 2).”
BackgroundInfluentialSaftien, A., Puschhof, J., & Elinav, E. (2023) · Gut · doi:10.1136/gutjnl-2022-327952 · Cited by 70
Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
Carlsen, L., Huntington, K. E., & El‐Deiry, W. S. (2022) · Cancers · doi:10.3390/cancers14041028 · Cited by 74
“pseudolongum produced inosine, which translocated systemically after ICB-induced gut barrier impairment to activate anti-tumor T cells [197].”
BackgroundA guide to germ‐free and gnotobiotic mouse technology to study health and disease
Jans, M., & Vereecke, L. (2024) · FEBS Journal · doi:10.1111/febs.17124 · Cited by 69
“Inosine-producing bacteria have been shown to enhance the effect of ICI therapy in CRC, bladder cancer and melanoma [205].”
Yuan, L., Pan, L., Wang, Y., Zhao, J., Fang, L., Zhou, Y., Xia, R., Ma, Y., Jiang, Z., Xu, Z., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00746-0 · Cited by 74
“Metabolomic analysis revealed that all metabolites related to arginine metabolism are consistently upregulated in tumour samples, and the microbiome plays a crucial role in this process, particularly in Cluster IV tumour samples enriched with Streptococcus .”
Kim, Y. J., Lee, J., Lee, J. J., Jeon, S. M., Silwal, P., Kim, I. S., Kim, H. J., Park, C. R., Chung, C., Han, J. E., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2073132 · Cited by 77
“pseudolongum increases the expression of T-bet, the Th1 master transcriptional factor, in CD4 T cells of the small intestinal lamina propria, but not in the spleen.(49) In addition, oral gavage of B.”
BackgroundInfluentialThe Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment
Luu, M., Schütz, B., Lauth, M., & Visekruna, A. (2023) · Cancers · doi:10.3390/cancers15051588 · Cited by 70
“In this study, inosine strongly enhanced the efficacy of ICI therapy in several experimental tumor models by modulating T cells via adenosine A2A receptors [82].”
BackgroundJennings, M. R., Munn, D. H., & Blazeck, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003013 · Cited by 69
Huyghe, N. D., Benidovskaya, E., Stevens, P., & den Eynde, M. V. (2022) · Cancers · doi:10.3390/cancers14092241 · Cited by 67
Jaye, K. M., Chang, D., Li, C. G., & Bhuyan, D. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169490 · Cited by 66
“The influence of inosine on T cell differentiation was dependent upon co-stimulation by other immune factors, sufficient IFN-γ production to increase anticancer immunity, and IL-12 receptor interaction to ensure TH1 differentiation by inosine [74].”
BackgroundInfluentialImmunological classification of tumor types and advances in precision combination immunotherapy
Ren, X., Guo, S., Guan, X., Kang, Y., Liu, J., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790113 · Cited by 62
“Spermidine and vitamin B6 generated by polyamines are capable of stimulating autophagy (24, 25).”
Background
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.